|
Gene: CD3EAP |
Gene summary for CD3EAP |
Gene summary. |
Gene information | Species | Human | Gene symbol | CD3EAP | Gene ID | 10849 |
Gene name | RNA polymerase I subunit G | |
Gene Alias | ASE-1 | |
Cytomap | 19q13.32 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O15446 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10849 | CD3EAP | LZE4T | Human | Esophagus | ESCC | 1.29e-07 | -4.52e-02 | 0.0811 |
10849 | CD3EAP | LZE20T | Human | Esophagus | ESCC | 8.85e-03 | -7.90e-02 | 0.0662 |
10849 | CD3EAP | LZE24T | Human | Esophagus | ESCC | 1.89e-02 | -9.02e-03 | 0.0596 |
10849 | CD3EAP | P1T-E | Human | Esophagus | ESCC | 1.53e-04 | 2.28e-01 | 0.0875 |
10849 | CD3EAP | P2T-E | Human | Esophagus | ESCC | 5.41e-16 | 8.40e-02 | 0.1177 |
10849 | CD3EAP | P4T-E | Human | Esophagus | ESCC | 9.00e-08 | 1.59e-01 | 0.1323 |
10849 | CD3EAP | P5T-E | Human | Esophagus | ESCC | 1.95e-14 | 3.41e-01 | 0.1327 |
10849 | CD3EAP | P8T-E | Human | Esophagus | ESCC | 6.03e-17 | 2.60e-01 | 0.0889 |
10849 | CD3EAP | P9T-E | Human | Esophagus | ESCC | 2.92e-11 | 8.63e-03 | 0.1131 |
10849 | CD3EAP | P10T-E | Human | Esophagus | ESCC | 9.02e-20 | 3.66e-01 | 0.116 |
10849 | CD3EAP | P11T-E | Human | Esophagus | ESCC | 3.13e-05 | 3.75e-01 | 0.1426 |
10849 | CD3EAP | P12T-E | Human | Esophagus | ESCC | 9.59e-04 | -9.47e-03 | 0.1122 |
10849 | CD3EAP | P15T-E | Human | Esophagus | ESCC | 6.16e-07 | 9.22e-02 | 0.1149 |
10849 | CD3EAP | P16T-E | Human | Esophagus | ESCC | 9.30e-06 | -4.71e-02 | 0.1153 |
10849 | CD3EAP | P20T-E | Human | Esophagus | ESCC | 7.62e-08 | 5.15e-02 | 0.1124 |
10849 | CD3EAP | P21T-E | Human | Esophagus | ESCC | 1.41e-10 | 9.22e-02 | 0.1617 |
10849 | CD3EAP | P22T-E | Human | Esophagus | ESCC | 1.25e-15 | 1.38e-01 | 0.1236 |
10849 | CD3EAP | P23T-E | Human | Esophagus | ESCC | 2.56e-10 | 2.20e-01 | 0.108 |
10849 | CD3EAP | P24T-E | Human | Esophagus | ESCC | 7.09e-07 | 1.40e-01 | 0.1287 |
10849 | CD3EAP | P26T-E | Human | Esophagus | ESCC | 1.52e-10 | 1.44e-01 | 0.1276 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD3EAP | SNV | Missense_Mutation | c.1114N>A | p.Glu372Lys | p.E372K | O15446 | protein_coding | tolerated(0.59) | benign(0) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
CD3EAP | SNV | Missense_Mutation | c.783A>T | p.Lys261Asn | p.K261N | O15446 | protein_coding | tolerated(0.19) | benign(0) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
CD3EAP | SNV | Missense_Mutation | c.197N>T | p.Ser66Phe | p.S66F | O15446 | protein_coding | deleterious(0.04) | possibly_damaging(0.885) | TCGA-GM-A2DO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR | |
CD3EAP | insertion | Nonsense_Mutation | novel | c.991_992insTCCACGACCATTAATCCTGCAACCTAAGCTTGCTCATTTATGTT | p.Lys331IlefsTer5 | p.K331Ifs*5 | O15446 | protein_coding | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | ||
CD3EAP | insertion | Frame_Shift_Ins | novel | c.576_577insCCAATGGACC | p.Val193ProfsTer88 | p.V193Pfs*88 | O15446 | protein_coding | TCGA-BH-A0E7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
CD3EAP | SNV | Missense_Mutation | rs372336084 | c.1483N>A | p.Glu495Lys | p.E495K | O15446 | protein_coding | tolerated(0.12) | benign(0.069) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CD3EAP | SNV | Missense_Mutation | c.1050G>C | p.Glu350Asp | p.E350D | O15446 | protein_coding | deleterious_low_confidence(0) | benign(0.327) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CD3EAP | SNV | Missense_Mutation | rs752873305 | c.571N>A | p.Glu191Lys | p.E191K | O15446 | protein_coding | deleterious(0.01) | benign(0.381) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
CD3EAP | SNV | Missense_Mutation | novel | c.833N>G | p.Thr278Ser | p.T278S | O15446 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-VS-A9UP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
CD3EAP | SNV | Missense_Mutation | c.1050G>C | p.Glu350Asp | p.E350D | O15446 | protein_coding | deleterious_low_confidence(0) | benign(0.327) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |